

Inventor: William D. Huse
Serial No.: 08/790,540
Filed: January 30, 1997
Page 2

E1
identity with that] shown in Figure 1A (SEQ ID NO:2), said variable region amino acid sequence having a framework sequence having 88% or greater identity with the framework sequence of SEQ ID NO:2, and at least one LM609 CDR-grafted light chain polypeptide comprising a variable region amino acid sequence [having greater than 79% identity with that] shown in Figure 1B (SEQ ID NO:4), said variable region amino acid sequence having a framework sequence having 79% or greater identity with the framework sequence of SEQ ID NO:4, or a functional fragment thereof, said LM609 CDR-grafted antibody or functional fragment thereof having integrin $\alpha_v\beta_3$ binding activity, integrin $\alpha_v\beta_3$ binding specificity or integrin $\alpha_v\beta_3$ -inhibitory activity, wherein said variable region amino acid sequences encoding said heavy and light chain polypeptides are non-mouse sequences.

E2
3. (Three Times Amended) A nucleic acid encoding a LM609 CDR-grafted heavy chain polypeptide comprising a LM609 CDR-grafted heavy chain variable region nucleotide sequence, or a modification [thereof that] of said nucleotide sequence wherein said modification does not change the encoded amino acid sequence, shown in Figure 1A (SEQ ID NO:1) or a fragment thereof.

4. (Three Times Amended) The nucleic acid of claim 3, wherein said fragment further comprises a nucleic acid encoding a nucleotide sequence, or a modification [thereof that] of said nucleotide sequence wherein said modification does not change the encoded amino acid sequence, as the variable region of said LM609 CDR-grafted heavy chain polypeptide (SEQ ID NO:1).

Inventor: William D. Huse
Serial No.: 08/790,540
Filed: January 30, 1997
Page 3

6. (Three Times Amended) A nucleic acid encoding a LM609 CDR-grafted light chain polypeptide comprising a LM609 CDR-grafted light chain variable region nucleotide sequence, or a modification [thereof that] of said nucleotide sequence wherein said modification does not change the encoded amino acid sequence, shown in Figure 1B (SEQ ID NO:3) or a fragment thereof.

7. (Three Times Amended) The nucleic acid of claim 6, wherein said fragment further comprises a nucleic acid encoding a nucleotide sequence, or a modification [thereof that] of said nucleotide sequence wherein said modification does not change the encoded amino acid sequence, as the variable region of said LM609 CDR-grafted light chain polypeptide (SEQ ID NO:3).

9. (Three Times Amended) A nucleic acid encoding a LM609 CDR-grafted antibody heavy chain polypeptide comprising a nucleotide sequence encoding a LM609 CDR-grafted heavy chain variable region amino acid sequence having [greater than] 88% or greater identity with that shown in Figure 1A (SEQ ID NO:2) or fragment thereof, wherein said variable region amino acid sequence encoding said heavy chain polypeptide is a non-mouse sequence and wherein said nucleic acid encodes a heavy chain polypeptide of an antibody having integrin $\alpha_v\beta_3$ binding activity, integrin $\alpha_v\beta_3$ binding specificity, or integrin $\alpha_v\beta_3$ -inhibitory activity.

Inventor: William D. Huse
Serial No.: 08/790,540
Filed: January 30, 1997
Page 4

85
12. (Three Times Amended) A nucleic acid encoding a LM609 CDR-grafted antibody light chain polypeptide comprising a nucleotide sequence encoding a LM609 CDR-grafted light chain variable region amino acid sequence having [greater than] 79% or greater identity with that shown in Figure 1B (SEQ ID NO:4) or fragment thereof, wherein said variable region amino acid sequence encoding said light chain polypeptide is a non-mouse sequence and wherein said nucleic acid encodes a light chain polypeptide of an antibody having integrin $\alpha_v\beta_3$ binding activity, integrin $\alpha_v\beta_3$ binding specificity, or integrin $\alpha_v\beta_3$ -inhibitory activity.

86
15. (Three Times Amended) A LM609 CDR-grafted heavy chain polypeptide comprising a variable region amino acid sequence having [greater than] 88% or greater identity with that shown in Figure 1A (SEQ ID NO:2) or functional fragment thereof, wherein said variable region amino acid sequence encoding said heavy chain polypeptide is a non-mouse sequence and wherein an antibody comprising said heavy chain polypeptide has integrin $\alpha_v\beta_3$ binding activity, integrin $\alpha_v\beta_3$ binding specificity, or integrin $\alpha_v\beta_3$ -inhibitory activity.